TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

135 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • DepressionAnxiety

    Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

    Testing whether therapy sessions can help teens and young adults with sickle cell cope with

    📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →

    The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.

    ✓ Study care freePhase 1Ages 14–21Learn more →
  • Depression

    The Role of mGluR5 in CBT-I

    Testing how a brain receptor may affect CBT-I for insomnia in people with depression

    📍 Stony Brook University: Dept of Psychiatry · Stony Brook, NY · Get directions →

    This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    📍 Mayo Clinic in Arizona · Scottsdale, AZ · +4 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Depression

    Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

    Testing brain scan and EEG measures to predict response to depression treatment

    📍 Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX · Get directions →

    The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Depression

    Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

    Testing whether a brain receptor change affects ketamine’s effect on depression

    📍 Yale University · New Haven, CT · Get directions →

    The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • COPD (chronic lung disease)

    Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

    Testing how a genetic change in alpha-1 antitrypsin affects immune and lung responses to a pneumonia

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • Depression

    Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

    Testing how dimethyltryptamine affects safety and depression symptoms

    📍 Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT · Get directions →

    The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects.

    ✓ Study care freePhase 1Ages 21–65Learn more →
  • Depression

    Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

    Testing how feasible it is to prescribe antidepressants after fragility fractures in adults 50 and

    📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →

    The goal of this pilot study is to learn about the feasibility about prescribing anti-depressants at discharge in patients aged 50 years and older with a lower extremity fragility fracture. The main questions it aims to answer are: * What are the obstacles to enrolling patients and prescribing anti-depressants among older adults?

    ✓ Study care freePhase 4Ages 65+Learn more →
  • Multiple sclerosis (MS)

    📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →

    This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Depression

    Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

    Testing whether a low-dose ketamine IV treatment is safe and workable in the ER for people with

    📍 University of Kansas Strawberry Hill Campus · Kansas City, KS · +1 more US site · Get directions →

    There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

    Testing safety of a new immune cell therapy in adults with multiple sclerosis

    📍 Research Site · Tucson, AZ · +8 more US sites · Get directions →

    This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Depression

    Dopaminergic Therapy for Anhedonia - 2

    Testing an 8-week treatment using L-DOPA for depression with low pleasure and high inflammation

    📍 Emory University Hospital · Atlanta, GA · Get directions →

    The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks.

    ✓ Study care freePhase 4Ages 25–55Learn more →
  • Depression

    Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression

    Testing how one-time exercise and ibuprofen affect bipolar depression symptoms

    📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →

    This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • DepressionAnxiety

    ACT for Individuals With MNCD and Their Care Partners

    Testing acceptance commitment therapy for depression and anxiety in dementia

    📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →

    This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Depression

    RCT of Psilocybin-assisted CBT for Depression

    Testing psilocybin with cognitive-behavioral therapy for depression

    📍 UCLA Semel Institute · Los Angeles, CA · Get directions →

    The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.

    ✓ Study care freePhase 1Ages 21–60Learn more →
  • Depression

    Identifying and Treating Depression in the Orthopaedic Trauma Population

    Testing how orthopedic trauma teams can screen for depression and treat it with medication

    📍 Wake Forest University Health Sciences · Winston-Salem, NC · Get directions →

    The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

    Testing the safety and effects of KITE-363 in people with multiple sclerosis

    📍 Stanford Neuroscience Health Center · Palo Alto, CA · +3 more US sites · Get directions →

    This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Multiple sclerosis (MS)

    A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

    Testing a CD19 CAR-T cell treatment for progressive multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · Get directions →

    A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Kidney disease

    📍 SouthCoast Research Center, Inc. · Miami, FL · +1 more US site · Get directions →

    The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression.

    ✓ Study care freePhase 1Ages 35–75Learn more →
  • Depression

    Psilocybin for Treatment-Resistant Depression in Autism

    Testing psilocybin plus talk therapy for depression in autistic adults

    📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →

    We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • COPD (chronic lung disease)Asthma

    The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

    Testing whether positive airway pressure helps a lung medicine (NAC) reach mucus plugs in asthma or

    📍 UCSF Airway Clinical Research Center · San Francisco, CA · Get directions →

    The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.

    ✓ Study care freePhase 4Ages 18–85Learn more →
  • Kidney disease

    Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.

    Testing whether exercise during dialysis and creatine help people with chronic kidney disease

    📍 IMSS-Bienestar State Haemodialysis Centre · Colima, Coliima · Get directions →

    This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. The study will compare the independent and combined effects of these interventions over an 8-week period to determine their potential benefits in this patient population.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Depression

    DBS for Depression

    Testing whether deep brain stimulation is safe and feasible for severe depression that hasn’t

    📍 Zucker Hillside Hospital · Queens, NY · Get directions →

    The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression?

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Depression

    Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

    Testing whether donor stem cells are safe and helpful for hard-to-treat bipolar depression

    📍 The University of Texas Health Science Center at Houston · Houston, TX · Get directions →

    The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Kidney disease

    A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

    Testing how a diabetes medicine in the bloodstream changes in kidney disease

    📍 Floridian Clinical Research, LLC · Miami Lakes, FL · +1 more US site · Get directions →

    The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Depression

    Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

    Comparing best step-by-step treatments for depression with anxiety

    📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →

    Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.

    ✓ Study care freePhase 4Ages 18–50Learn more →
  • Depression

    Pharmacologic Augmentation of TMS for Depression With D-serine

    Testing whether adding D-serine to TMS sessions helps depression

    📍 McLean Hospital · Belmont, MA · Get directions →

    The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Multiple sclerosis (MS)

    A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

    Testing how a new medicine given through a vein or under the skin is handled and tolerated in people

    📍 Stanford University Medical Center · Stanford, CA · +4 more US sites · Get directions →

    The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    Testing whether TRX319 is safe for people with progressive multiple sclerosis

    📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →

    The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Depression

    Neural Response to Inflammatory Challenge in Major Depressive Disorder

    Testing brain and immune responses to an inflammation trigger in depression

    📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →

    This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Depression

    Neural Circuit Effects of Ketamine in Depression

    Testing how ketamine affects brain activity and depression symptoms

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Kidney disease

    Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)

    Testing a daily anti-inflammatory medicine to reduce heart and blood vessel injury in people with

    📍 University of Alberta Hospital · Edmonton, Alberta · Get directions →

    Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0011 · Birmingham, AL · +16 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Depression

    A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    Comparing a drug called AXS-05 with bupropion to prevent depression relapse

    📍 Clinical Research Site · Bellflower, CA · +39 more US sites · Get directions →

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • DepressionAnxiety

    Open-Label Psilocybin Study in Transdiagnostic Population

    Testing psilocybin for safety and symptom changes in people with depression or anxiety

    📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →

    The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

    Testing a GE xenokidney transplant in people with ESRD for safety and effectiveness

    📍 Northwestern Memorial Hospital · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Dementia / Alzheimer'sMultiple sclerosis (MS)

    Exploring the Utility of [18F]3F4AP for Demyelination Imaging

    Testing how an imaging tracer works in people with memory loss and multiple sclerosis

    📍 Yale University PET Center · New Haven, CT · Get directions →

    The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • DepressionAnxiety

    Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

    Testing a chatbot to support people using cannabis with anxiety or depression

    📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →

    This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Depression

    Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

    Testing a biomarker prediction tool to forecast depression treatment outcomes

    📍 University of Calgary · Calgary, Alberta · Get directions →

    This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome for patients experiencing a major depressive episode (MDE).

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • COPD (chronic lung disease)

    📍 Equity Medical Bowling Green · Bowling Green, KY · +2 more US sites · Get directions →

    Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Depression

    Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

    Testing how psilocybin affects the brain in people with hard-to-treat bipolar depression

    📍 Toronto Western Hospital - University Health Network · Toronto, Ontario · Get directions →

    This study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and integration psychotherapy sessions (psilocybin-assisted psychotherapy, or PAP). Using fMRI (functional magnetic resonance imaging), the findings of this study will provide data on the neurobiological mechanism of psilocybin in TRBD.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Kidney disease

    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

    Testing the safety and side effects of OJR520 and how the body handles it in people with chronic

    📍 Quotient Sciences Sea View · Miami, FL · Get directions →

    The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

    Testing a new kidney tissue transplant to treat end-stage kidney disease

    📍 New York University Langone Health · New York, NY · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Kidney disease

    📍 Research Site · Glendale, CA · +4 more US sites · Get directions →

    This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • COPD (chronic lung disease)

    Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

    Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure

    💵 May compensate

    📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →

    This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.

    ✓ Study care freePhase 4Ages 35–85WomenLearn more →
  • Kidney disease

    BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

    Testing a vaccine to prevent Epstein-Barr virus cancer in transplant patients

    📍 Ohio State University Comprehensive Cancer Center · Columbus, OH · Get directions →

    This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients awaiting a solid organ transplant. Currently, patients who receive an organ transplant receive immune suppression therapy which can make it harder for the body to fight infections.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • COPD (chronic lung disease)

    Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

    Comparing nebulizer and inhaler treatments for COPD symptoms

    📍 The University of Tennessee Graduate School of Medicine · Knoxville, TN · Get directions →

    The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Kidney disease

    A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

    Testing the safety and how an oral medicine moves through the body in adults with severe kidney

    📍 Floridian Clinical Research · Miami Lakes, FL · +1 more US site · Get directions →

    This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Depression

    Theta-Burst Stimulation to Treat Depression

    Testing a non-invasive brain stimulation approach to treat depression

    📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →

    The goal of this clinical trial is to explore the effects of non-invasive brain stimulation protocols using intermittent theta-burst stimulation (iTBS) on brain plasticity and depression severity in depressed individuals aged 18 to 50 years old. Brain plasticity is the brain's ability to change through growth or reorganization.

    ✓ Study care freePhase 1Ages 18–50Learn more →
  • Depression

    Personalized Ultrasonic Brain Stimulation for Depression (R61)

    Testing a personalized, noninvasive brain stimulation for depression

    📍 University of Utah · Salt Lake City, UT · Get directions →

    This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Showing the first 60 of 135. Add filters or a location to narrow down.